Cisplatin Research

Cisplatin induces mitochondrial damage and hippocampal neurotoxicity: a potential mechanism for chemotherapy-related cognitive impairment

Loss of MGMT promoter methylation and resistance to cisplatin in non-seminomatous germ cell tumors

Single cell cisplatin measurements by ICP-MS

Chloroquine-induced lysosomal membrane permeabilization restores sensitivity to cisplatin in refractory lung cancer cells

Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity without Compromising Cisplatin Anticancer Properties

Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity without Compromising Cisplatin Anticancer Properties

Pharmacological focal adhesion kinase (FAK) inhibition suppresses cisplatin-resistant human ovarian carcinoma growth.

A comparison of the mechanisms and cytotoxic activity of dianhydrogalactitol (VAL-083) to cisplatin in ovarian tumor models harboring wild-type and mutant p53.

A novel assay to predict cisplatin resistance in cancer cells

Analysis of continuous firstline treatment with docetaxel and carboplatin for advanced nonsmall cell lung cancer

A phase II trial of decitabine in combination with carboplatin vs carboplatin alone in patients with ovarian cancer

Risk Stratification Protocol For Carboplatin and Oxaliplatin Hypersensitivity Reactions With Repeat Skin Testing Improves Care

Chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer

Economic impact of a genetic test for cisplatin-induced ototoxicity - Nature

Magnetic medicines hit the cancerous spot

New platinum drug candidate shows promise against cancer

Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy

MIT cancer biologists have shown how resistance to cisplatin arises

Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity.

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

Cisplatin Causes Mitochondrially Mediated Hippocampal Damage.

Why cancer drugs lose their power - news report from MIT

Researchers design a new version of cisplatin that spares the kidneys, letting doctors use higher doses - more from MIT

Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.

Bim protein degradation contributes to cisplatin resistance.

Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents.

Meta-analysis finds cisplatin improves post-operative survival in patients with non-small lung cancer.

 

This Website

About Us
Resources
Spanish